| Q38308978 | Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types |
| Q91723119 | Comprehensive manipulation of glycosylation profiles across development scales |
| Q46879419 | Effect of glycosylation on antibody function: implications for genetic engineering |
| Q37417435 | Emerging methods for the production of homogeneous human glycoproteins |
| Q26799266 | Fc glycans of therapeutic antibodies as critical quality attributes |
| Q38086151 | Glycans-by-design: engineering bacteria for the biosynthesis of complex glycans and glycoconjugates |
| Q59132146 | Improving Immunotherapy Through Glycodesign |
| Q60919664 | In Vivo Glycan Engineering via the Mannosidase I Inhibitor (Kifunensine) Improves Efficacy of Rituximab Manufactured in Plants |
| Q30835165 | Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity |
| Q72752083 | Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions |
| Q51284070 | Optimization of humanized IgGs in glycoengineered Pichia pastoris. |
| Q34018403 | Plants as bioreactors: Recent developments and emerging opportunities |
| Q41614382 | Production of a functional monoclonal antibody recognizing human colorectal carcinoma cells from a baculovirus expression system |
| Q98466487 | Protein Glycoengineering: An Approach for Improving Protein Properties |
| Q38224264 | Recent advances in the understanding of biological implications and modulation methodologies of monoclonal antibody N-linked high mannose glycans |
| Q90027632 | The history of IgG glycosylation and where we are now |